• THE NEXT GENERATION OF IMMUNOTHERAPY

    Salspera is developing its platform of orally administered tumor microbiome immunotherapies to tackle a wide range of solid tumor cancers.

  • A leading company in tumor microbiome immunotherapy.

    Salspera is a private, clinical stage company developing its platform of novel microbiome immunotherapies in solid tumor indications.

    Novel Therapy

    This innovative approach to immunotherapy has been shown to be safe and effective in human clinical trials and through years of published animal studies.

    Clinical Stage

    Salspera’s lead candidate, Saltikva®, is an oral immunotherapy that is currently in a Phase 2 study in patients with metastatic pancreatic cancer

    Immunotherapy Platform

    Salspera is developing its novel bacterial-based immunotherapy platform in additional solid tumor indications

  • It's time for cancer therapy to work with the body, not against it.

    Salspera is a clinical-stage biotechnology company committed to developing novel therapies for solid tumor cancers. The company has a platform of tumor microbiome immunotherapies that have the potential to address a range of solid tumor cancers where unmet medical need is high. We believe microbial immunotherapies could be used to create a new category of medicines with significant potential to improve the lives of patients.

  • SALTIKVA

    Genetically engineered microbial therapy to release human Interleukin-2 within the tumor microenvironment

    Oral and Safe

    Saltikva is orally administered and is non-toxic with no observed adverse events to date

    Targeted

    Saltikva seeks and colonizes solid tumors and metastases with a 10:000:1 ratio over normal tissues

    Immunostimulatory

    Saltikva results in NK Cell activation following IL-2 expression; no systemic toxicity since IL-2 is only expressed in tumor and metastases

  • PIPELINE

    Our robust pipeline has development programs spanning multiple indications.

    Our Phase 2 study in stage 4 metastatic pancreatic cancer was initiated in October 2020. Saltikva is being tested in combination with current standard of care which consists of FOLFIRINOX or Gemcitabine, both chemotherapeutic regimens which patients are selected for depending on their comorbidity profile. This disease has a prevalence of roughly 225K patients in major markets (US/EU) and its prognosis is 11.1-month median survival (MS) for patients taking FOLFIRINOX and 6.8-month MS for patients taking Gemcitabine.
  • CLINICAL PUBLICATIONS

  • Orally Administered Multiple Dose Saltikva (Salmonella-IL2) in Conjunction with Folfirinox in a Patient with Stage IV Pancreatic Cancer: A Case Report

    Orally administered Saltikva resulted in a complete absence of metabolic tumor activity by PET scan, regression of metastatic tumor burden, and a strong NK cell mediated immune response in stage IV pancreatic cancer. Patient is currently in month 23 (compared to median survival of 11.1 months) and has not experienced any toxicity from the experimental treatment.

  • A Phase I, Dose Escalation, Single Dose Trial of Oral Attenuated Salmonella typhimurium Containing Human IL-2 in Patients With Metastatic Gastrointestinal Cancers

    Oral Saltikva resulted in a significant increase in NK and NK-T cells with no toxicity or adverse events observed in phase I safety trial.

  • Microbial Immunotherapy: Saltikva as a Novel Therapeutic for Solid Tumors

    Presented at 2021 EACR Conference (Defence is the Best Attack: Immuno-Oncology Breakthroughs)

  • PRECLINICAL PUBLICATIONS

    Saltzman DA, Augustin LB, Leonard AS, Mertensotto M, and Schottel J: Low Dose Chemotherapy Combined with Attenuated Salmonella Significantly Reduces Tumor Burden and is Less Toxic than High Dose Chemotherapy in an Autochthonous Murine Model of Breast Cancer. Surgery, 163(3):509-514, 2018. PMID 29229318

     

    Drees JJ, Mertensotto MJ, Augustin LB, Schottel JK. Saltzman DA: Attenuated Salmonella Vascular Disruption Enhances Bacterial Targeting of Autochthonous Tumors, 2015 Journal of Cancer, 6(9):843-848. PMID 26284135

     

    Drees J, Mertensotto M, Liu G, Panyam, J, Leonard A, Augustin L, Schottel J, and Saltzman D: Attenuated Salmonella enterica Typhimurium Reduces Tumor Burden in an Autochthonous Breast Cancer Model. Anticancer Research, 35(2):843-849, 2015. PMID 25667465

     

    Drees JJ, August LB, Mertensotto MJ, Schottel JL, Leonard AS, Saltzman DA: Soluble production of a biologically active single chain antibody against murine PDL-1 in E coli. Protein Expr Purif 94:60-66, 2014.

     

    Sorenson BS, Banton KL, Augustin LB, Frykman NL, McCulloch KA, Bulander RD, Wasiluk K, Leonard AS, Saltzman DA. Safety of an Attenuated Strain of Salmonella Typhimurium Expressing C-terminal Truncated Human IL-2: A Murine Infection Model. Biologics: Targets and Therapy. 2010 4:61-73.

     

    Brent S. Sorenson, BS, Kaysie L. Banton, MD, Natalie L Frykman, BS, Robert D. Acton MD, Arnold S. Leonard MD, PhD, Daniel A. Saltzman, MD, PhD. Attenuated Salmonella typhimurium with IL-2 gene Prevents the Establishment of Pulmonary Metastases in a Model of Osteosarcoma; J Ped Surg. 43(6): 1153-8. 2008.

     

    Brent S. Sorenson, BS, Kaysie L. Banton, MD, Natalie L Frykman, BS, Robert D. Acton MD, Arnold S. Leonard MD, PhD, Daniel A. Saltzman, MD, PhD. Attenuated Salmonella typhimurium with IL-2 gene Reduces Pulmonary Metastases in a Model of Osteosarcoma; Clinical Orthopaedics and Related Research. 466(6): 1285-91. 2008.

     

    Barnett SJ, Soto III LJ, Sorenson BS, Nelson BW, Leonard AS, Saltzman DA. Salmonella typhimurium Invades and Decreases Tumor Burden in Neuroblastoma. Journal of Pediatric Surgery 40(6): 993-998, 2005.

     

    Soto LJ, Sorenson BS, Nelson BW, Leonard AS, Saltzman DA; Generation of Immunity to Hepatic Metastases by Attenuated Salmonella typhimurium, Ann Surg Onc, 11(2)suppl: S107, 2004.

     

    Soto LJ, Sorenson BS, Kim AS, Feltis BA, Leonard AS, and Saltzman DA: Attenuated Salmonella typhimurium prevents the Establishment of Unresectable Hepatic Metastases and Improves Survival in a Murine Model. Journal of Pediatric Surgery 38(7) 1075-1079, 2003.

     

    Feltis BA, Miller JS, Sahar DA, Kim AS, Saltzman DA, Leonard AS, Wells, CL, and Sielaff TD: Liver and Circulating NK1.1(+)CD3(-) Cells are Increased in Infection with Attenuated Salmonella typhimurium and are Associated with Reduced Tumor in Murine Liver Cancer. Journal of Surgical Research 107(1):101-7, 2002.

     

    Soto LJ, Sorenson BS, Kim AS, Feltis BA, Leonard AS, and Saltzman DA: Attenuated Salmonella typhimurium prevents the Establishment of Hepatic Colorectal Metastases and Improves Survival in a Murine Model. Tumor Biology 23:S1:30, 2002.

     

    Feltis BA, Sahr DA, Kim AS, Saltzman DA, Leonard AS, Sielaff TD: Cyclooxygenase 2 inhibition augments hepatic antitumor effect of oral Salmonella typhimurium in a model of mouse metastatic colon cancer. Diseases of the Colon and Rectum. 45(8):1023-8, 2002.

     

    Saltzman DA, Katsanis E, Heise CP, Hasz DE, Kelly SM, Curtiss R, Anderson PM, and Leonard AS: Hepatic and Splenic Colonization for the Attenuated Salmonella typhimurium Containing the Gene for Human Interleukin-2: A Novel Anti-Tumor Agent. Cancer Biotherapy and Radiopharmaceuticals, 12910:37-45, 1997.

     

    Saltzman DA, Katsanis E, Hasz DE, Vigdorovich V, Curtiss III RE, Kelly SM, Anderson PM, and Leonard AS: Anti-tumor Mechanisms of Attenuated Salmonella typhimurium Containing the Gene for Human Interleukin-2. Journal of Pediatric Surgery, 32(2):301-306, 1997.

     

    Saltzman DA, Heise CP, Hasz DE, Zebede M, Kelly SM, Curtiss III R, Leonard AS, and Anderson PM. Attenuated Salmonella typhimurium Containing Interleukin-2 Decreases Number of MC-38 Hepatic Metastases: A Novel Anti-tumor Agent. Cancer Biotherapy and Radiopharmaceuticals, 11(2)145-153, 1996.

  • Management

    Eddie Moradian, Ph.D.

    Salspera Co-founder and Chief Executive Officer

    Dr. Moradian is the co-founder and Chief Executive Officer of Salspera. Founding of over two-dozen companies over a career spanning nearly 25 years in the healthcare, pharma and biotechnology industry, Dr. Moradian provides Salspera with the leadership and management experience needed to forge the path forward. Results- and metrics-oriented as well as process driven in management, he has created companies that have each garnered high respect in their industrial area, from customers, trade partners, as well as collaborators and competitors. This management experience will benefit Salspera in its effort to pursue value creation in the most efficient ways and with the participation of collaborators. Dr. Moradian received his Ph.D. in biotechnology in 1991 from the Swiss Federal Institute of Technology in Zurich, Switzerland and is a member of various leading industrial organizations.

    Daniel Saltzman, M.D., Ph.D.

    Salspera Co-founder and Chief Medical Officer

    Dr. Saltzman is the co-founder and Chief Medical Officer of Salspera. Considered a renowned expert in the field of microbial immunotherapy, he has led an experimental therapeutic cancer immunotherapy laboratory for the last two decades. Specifically, he has studied the use of attenuated Salmonella as a tumor-targeted vehicle to carry immune modulating proteins directly to the tumor microenvironment. Dr. Saltzman is the Chief of Pediatric Surgery at the University of Minnesota Medical School/University of Minnesota Masonic Children’s Hospital. He holds the AS Leonard Endowed Chair in Pediatric Surgery. A native of the Panama Canal Zone, Dr. Saltzman obtained his B.S., M.D., and Ph.D. degrees from the University of Minnesota. He completed his surgical residency at the University of Minnesota and a Pediatric Surgery Fellowship at the University of Arkansas. Dr. Saltzman has authored over 130 articles (manuscripts and abstracts) published in the medical literature, has written 10 book chapters, and holds 5 patents. Dr. Saltzman is an examiner for the Pediatric Surgery Portion of the American Board of Surgery. He sits on the editorial board of the Journal of Surgical Education and is an ad hoc reviewer for the Journal of Pediatric Surgery and five other journals. In addition, he has an active clinical practice where Dr. Saltzman has expertise in Pediatric Cancers, Gastrointestinal Disorders, and Chest Wall Deformities. The Saltzman Research Lab is considered a world leader in the use of bacteria to deliver immunomodulatory proteins directly to cancers. He wrote the very first journal article ever published on the use of Salmonella for cancer therapy. His lab has developed a Salmonella based cancer treatment strategy that is currently in clinical human trials.

    M. Chandler Glass

    Business Development Manager

    Chandler Glass is the Business Development Manager at Salspera. He joined Salspera in March 2020 and is responsible for leading the company’s business and corporate development, alliance management, and strategy functions across the company’s research and development portfolio. Prior to joining Salspera in 2020, he worked in corporate development at Eloxx Pharmaceuticals, a clinical stage biotechnology company developing treatments for rare and ultra-rare nonsense mutation mediated diseases. He received his B.S. in Biomedical Engineering from Tufts University.

  • Strategic Partnership Interests

    Contact us at bd@salspera.com

    Partner US/EU and/or RoW Commercialization of Saltikva® in Stage IV Metastatic Pancreatic Cancer

    • Partners with companies that have existing solid tumor salesforces and commercialization expertise in major (US/EU) and RoW markets

    Partner Saltikva® in Additional Solid Tumor Indications

    • Partnerships for Saltikva® development in indications not currently being explored (i.e. GI tract cancers)
    • Partnership for Saltikva® as a combination therapy with other clinical stage or approved solid tumor assets

    Partner Other Salspera Constructs in Additional Solid Tumor Indications

    • Partnering of Salspera pipeline for development of additional solid tumor therapies
    • Combination therapy with other solid tumor assets

    Partner Salspera Construct with Other Company's Biologic to Improve its Delivery Profile

    • Use genetically engineered microbial immunotherapy to express partner’s biologic drug for superior administration, safety, and efficacy
  • Microbial Immunotherapy Blog

    Stay up to date with recent advances in the field of microbial immunotherapy.

    Oakdale, MN, September 27th, 2021 – Salspera, LLC, a clinical stage biotechnology developing orally administered tumor microbiome immunotherapies, today announced positive topline data from its phase 2 trial of Saltikva in first line metastatic pancreatic cancer. The company also announced that...
    Oakdale, MN, June 09, 2021 – Salspera announced today that it has been selected to deliver a company presentation at 2021 BIO Digital, the premier biotech event. BIO Digital is scheduled June 10-11 & 14-18, 2021. The presentation will be available to registered attendees at 9 am ET June 10 here...
    OAKDALE, MN., June 01, 2021 -- Salspera, LLC, a clinical-stage biotechnology company pioneering the discovery and development of its platform of tumor microbiome immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug application...
    More Posts
  • CONTACT US

    Salspera, LLC
     
    3510 Hopkins Place N.
    Oakdale, MN 55128
     

    All Posts
    ×